Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus

Ronald F van Vollenhoven, Kenneth C Kalunian, Thomas Dörner, Bevra H Hahn, Yoshiya Tanaka, Robert M Gordon, Cathye Shu, Kaiyin Fei, Sheng Gao, Loqmane Seridi, Patrick Gallagher, Kim Hung Lo, Pamela Berry, Qing C Zuraw, Ronald F van Vollenhoven, Kenneth C Kalunian, Thomas Dörner, Bevra H Hahn, Yoshiya Tanaka, Robert M Gordon, Cathye Shu, Kaiyin Fei, Sheng Gao, Loqmane Seridi, Patrick Gallagher, Kim Hung Lo, Pamela Berry, Qing C Zuraw

Abstract

Objective: Evaluate the efficacy and safety of ustekinumab, an anti-interleukin-12/23 p40 antibody, in a phase 3, randomised, placebo-controlled study of patients with active systemic lupus erythematosus (SLE) despite receiving standard-of-care.

Methods: Active SLE patients (SLE Disease Activity Index 2000 (SLEDAI-2K) ≥6 during screening and SLEDAI-2K ≥4 for clinical features at week 0) despite receiving oral glucocorticoids, antimalarials, or immunomodulatory drugs were randomised (3:2) to receive ustekinumab (intravenous infusion ~6 mg/kg at week 0, followed by subcutaneous injections of ustekinumab 90 mg at week 8 and every 8 weeks) or placebo through week 48. The primary endpoint was SLE Responder Index (SRI)-4 at week 52, and major secondary endpoints included time to flare through week 52 and SRI-4 at week 24.

Results: At baseline, 516 patients were randomised to placebo (n=208) or ustekinumab (n=308). Following the planned interim analysis, the sponsor discontinued the study due to lack of efficacy but no safety concerns. Efficacy analyses included 289 patients (placebo, n=116; ustekinumab, n=173) who completed or would have had a week 52 visit at study discontinuation. At week 52, 44% of ustekinumab patients and 56% of placebo patients had an SRI-4 response; there were no appreciable differences between the treatment groups in the major secondary endpoints. Through week 52, 28% of ustekinumab patients and 32% of placebo patients had a British Isles Lupus Assessment Group flare, with a mean time to first flare of 204.7 and 200.4 days, respectively. Through week 52, 70% of ustekinumab patients and 74% of placebo patients had ≥1 adverse event.

Conclusions: Ustekinumab did not demonstrate superiority over placebo in this population of adults with active SLE; adverse events were consistent with the known safety profile of ustekinumab.

Trial registration number: NCT03517722.

Keywords: autoimmune diseases; biological therapy; lupus erythematosus, systemic.

Conflict of interest statement

Competing interests: RFvV has received grants from Bristol Myers Squibb, GlaxoSmithKline, MSD, Pfizer, Roche, and UCB; consulting fees from AbbVie, AstraZeneca, Biogen, BMS, Galapagos, Janssen, Miltenyi, Pfizer, UCB; honoraria/speaking fees from AbbVie, Galapagos, GlaxoSmithKline, Janssen, Pfizer, R-Pharma, and UCB. KCK has received grants from Acceleron, Alexion, Alpine, Horizon, Idorsia, Kirin, the National Institutes of Health, Provention Bio, Sanford Consortium, and UCB; consulting fees from Amgen, AstraZeneca, Aurinia, Biogen, Bristol Myers Squibb, Eli Lilly, EquilliumBio, Genentech/Roche, Gilead, GlaxoSmithKline, Janssen, Kang Pu, KezarBio, Merck, and Novartis. TD has received consulting fees, speaking fees, and/or honoraria from AbbVie, Celgene/Bristol Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen, Novartis, Genentech/Roche, and UCB and support for conducting clinical studies (paid to the university) from AbbVie, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Novartis, Roche and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GlaxoSmithKline and UCB. YT has received speaking fees and/or honoraria from AbbVie, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, GlaxoSmithKline, Mitsubishi-Tanabe, and Pfizer; and received research grants from AbbVie, Asahi-Kasei, Boehringer-Ingelheim, Chugai, Daiichi-Sankyo, Eisai, and Takeda. RMG, CS, KF, SG, LS, PG, KHL and QCZ are employees of Janssen Research & Development and own stock in Johnson & Johnson, of which Janssen Research & Development, is a wholly owned subsidiary. PB is an employee of Immunology Strategic Market Access, Janssen Pharmaceutical Companies of Johnson & Johnson and owns stock in Johnson & Johnson.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Patient disposition of LOTUS participants. mFAS, (including patients who either completed their week 52 visit or would have had a week 52 visit at the time of study discontinuation by the sponsor). mFAS, modified full analysis set.
Figure 2
Figure 2
The proportion of patients achieving an SRI-4 composite response at week 52 (A) and week 24 (B), a reduction in glucocorticoid dose at week 40 that was sustained through week 52 (C), joint response at week 52 (D), CLASI response at week 52 (E), and a reduction in glucocorticoid dose at week 40 that was sustained through week 52 together with an SRI-4 composite response at week 52 (F). Analyses were performed using the modified Full Analysis Set population, excluding patients whose week 52 visit was projected to occur after the early study discontinuation by the sponsor. CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; SRI-4, Systemic Lupus Erythematosus Responder Index-4.
Figure 3
Figure 3
Time to first BILAG flare. BILAG, British Isles Lupus Assessment Group
Figure 4
Figure 4
Baseline serum concentrations of IFNα, IFNγ, p40, IL-17F and IL-22 in LOTUS patients and healthy controls and median change from baseline in serum concentrations of IFNγ and p40 through week 24. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the median. The upper line extends to the largest value ≤1.5 × IQR; the lower line extends to the smallest value ≤1.5 × IQR. Data beyond the end of the lines represents outlier points. **P

References

    1. Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun 2019;96:1–13. 10.1016/j.jaut.2018.11.001
    1. Benlysta: Package insert. Research Triangle Park, NC: GlaxoSmithKline, 2021.
    1. Saphnelo: Package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2021.
    1. Lupkynis: Package insert. Victoria, BC: Aurinia Pharmaceuticals Inc., 2021.
    1. Lopez R, Davidson JE, Beeby MD, et al. . Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology 2012;51:491–8. 10.1093/rheumatology/ker368
    1. Peschken CA, Wang Y, Abrahamowicz M, et al. . Persistent disease activity remains a burden for patients with systemic lupus erythematosus. J Rheumatol 2019;46:166–75. 10.3899/jrheum.171454
    1. Utset TO, Baskaran A, Segal BM, et al. . Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus. Lupus Sci Med 2015;2:e000058. 10.1136/lupus-2014-000058
    1. Dai H, He F, Tsokos GC, et al. . Il-23 limits the production of IL-2 and promotes autoimmunity in lupus. J Immunol 2017;199:903–10. 10.4049/jimmunol.1700418
    1. Qiu F, Song L, Yang N, et al. . Glucocorticoid downregulates expression of IL-12 family cytokines in systemic lupus erythematosus patients. Lupus 2013;22:1011–6. 10.1177/0961203313498799
    1. Wong CK, Lit LCW, Tam LS, et al. . Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for TH17-mediated inflammation in auto-immunity. Clin Immunol 2008;127:385–93. 10.1016/j.clim.2008.01.019
    1. Huang X, Hua J, Shen N, et al. . Dysregulated expression of interleukin-23 and interleukin-12 subunits in systemic lupus erythematosus patients. Mod Rheumatol 2007;17:220–3. 10.3109/s10165-007-0568-9
    1. Stelara: Package insert. Horsham, PA: Janssen Biotech, Inc., 2020.
    1. Grammer AC, Ryals MM, Heuer SE, et al. . Drug repositioning in SLE: crowd-sourcing, literature-mining and big data analysis. Lupus 2016;25:1150–70. 10.1177/0961203316657437
    1. van Vollenhoven RF, Hahn BH, Tsokos GC, et al. . Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol 2020;72:761–8. 10.1002/art.41179
    1. van Vollenhoven RF, Hahn BH, Tsokos GC, et al. . Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 2018;392:1330–9. 10.1016/S0140-6736(18)32167-6
    1. van Vollenhoven RF, Hahn BH, Tsokos GC, et al. . Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase II open-label extension study. J Rheumatol 2022;49:380–7. 10.3899/jrheum.210805
    1. Isenberg DA, Rahman A, Allen E, et al. . BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005;44:902–6. 10.1093/rheumatology/keh624
    1. Albrecht J, Taylor L, Berlin JA, et al. . The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005;125:889–94. 10.1111/j.0022-202X.2005.23889.x
    1. Strand V, Crawford B. Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Rev Pharmacoecon Outcomes Res 2005;5:317–26. 10.1586/14737167.5.3.317
    1. van Vollenhoven RF, Petri MA, Cervera R, et al. . Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343–9. 10.1136/annrheumdis-2011-200937
    1. Wallace DJ, Furie RA, Tanaka Y, et al. . Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018;392:222–31. 10.1016/S0140-6736(18)31363-1
    1. Stohl W, Schwarting A, Okada M, et al. . Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 2017;69:1016–27. 10.1002/art.40049
    1. Bruce IN, O'Keeffe AG, Farewell V, et al. . Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann Rheum Dis 2015;74:1706–13. 10.1136/annrheumdis-2013-205171
    1. Litwic AE, Sriranganathan MK, Edwards CJ. Race and the response to therapies for lupus: how strong is the evidence? Int J Clin Rheumtol 2013;8:471–81. 10.2217/ijr.13.41
    1. Cesaroni M, Seridi L, Loza MJ, et al. . Suppression of serum interferon-γ levels as a potential measure of response to ustekinumab treatment in patients with systemic lupus erythematosus. Arthritis Rheumatol 2021;73:472–7. 10.1002/art.41547
    1. Campbell K, Branigan P, Yang F. Selective IL-23 blockade with guselkumab (GUS) neutralizes Th17- and psoriasis-associated serum, cellular, and transcriptomic measures more potently than dual IL-12/23 blockade with ustekinumab (UST). Abstracts Exp Dermatol 2018;27:3–58.
    1. Siebert S, Loza MJ, Song Q. Ustekinumab and guselkumab treatment results in differences in serum IL17A, IL17F and CRP levels in psoriatic arthritis patients: a comparison from ustekinumab PH3 and guselkumab PH2 programs. Ann Rheum Dis 2019;78:A293.

Source: PubMed

3
Tilaa